Adverum Biotechnologies, Inc.
ADVM
|
$11.515
1.45%
25K
|
Health Technology
(0.0% 1d) (603.6% 1m) (1162.0% 1y) (0.0% 2d) (0.0% 3d) (-1.0% 7d) (-38.75% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 2,389,928,485
http://www.adverum.com
Sec Filling | Patents | 114 employees
(US) Adverum Biotechnologies, Inc. is a clinical-stage biotechnology company that engages in the development of novel gene therapies to treat patients with sight-threatening ophthalmic diseases. It focuses on treatment of wet age-related macular degeneration, alpha-1 antitrypsin deficiency, hereditary angioedema, friedreich's ataxia, severe allergy, color vision deficiency, and juvenile x-linked retinoschisis. The company was founded by Mark S. Blumenkranz, Thomas W. Chalberg, Jr., Mitchell H. Finer and Steven Daniel Schwartz on July 17, 2006 and is headquartered in Menlo Park, CA.
gene therapies macular treatment hereditary angioedema
add to watch list Paper trade email alert is off
Press-releases
Opthea Appoints John Han, PharmD, as VP Medical Affairs
Published: 2024-04-08 (Crawled : 23:00) - globenewswire.com
REGN | $900.22 -0.11% 150K
|
Health Technology
|
| O: 0.31%
H: 0.83%
C: 0.27%
OPT | $3.39 -0.29% 1.8K
|
Health Technology
|
| O: -4.22%
H: 5.96%
C: 5.96%
AMGN | $265.48 0.53% 360K
|
Health Technology
|
| O: 0.37%
H: 0.38%
C: 0.06%
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: -0.4%
H: 1.52%
C: -4.15%
medical
Adverum Biotechnologies Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Pipeline Highlights and Corporate Updates
Published: 2024-03-18 (Crawled : 20:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: -15.25%
H: 20.0%
C: 10.0%
biotechnologies year pipeline financial results
Adverum Biotechnologies to Participate in the TD Cowen 44th Annual Health Care Conference
Published: 2024-02-28 (Crawled : 21:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 0.51%
H: 3.54%
C: 0.0%
conference biotechnologies health care
Adverum Biotechnologies to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Published: 2024-02-12 (Crawled : 13:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 6.36%
H: 12.5%
C: 8.15%
conference biotechnologies life sciences
Adverum Biotechnologies Announces Positive Preliminary Efficacy and Safety Data from LUNA Phase 2 Trial of Ixo-vec in Patients with Wet AMD
Published: 2024-02-08 (Crawled : 12:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 4.98%
H: 0.68%
C: -33.22%
biotechnologies positive trial
Adverum Biotechnologies Announces $127.5 Million Private Placement Financing
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 20.42%
H: 22.22%
C: 11.7%
biotechnologies million
Adverum Biotechnologies will Host Webcast to Review LUNA Phase 2 Preliminary Efficacy and Safety Results on February 8, 2024
Published: 2024-02-01 (Crawled : 23:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 0.84%
H: 25.0%
C: 18.33%
biotechnologies review results
Adverum Biotechnologies Appoints Romuald Corbau, Ph.D. as Chief Scientific Officer
Published: 2024-01-29 (Crawled : 13:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 2.17%
H: 16.68%
C: 11.47%
biotechnologies
AAV Vectors in Gene Therapy Market is Predicted to Observe Skyrocketed Growth During the Study Period (2019-2032) | DelveInsight `
Published: 2024-01-16 (Crawled : 22:00) - prnewswire.com
SNYNF | News | $92.7 1.4K
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
LLY | News | $749.245 -0.2% 550K
|
Health Technology
|
| O: 0.77%
H: 0.17%
C: -1.65%
SNY | News | $45.445 -1.44% 2.6M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
RGNX | News | $16.67 -2.11% 150K
|
Health Technology
|
| O: -0.13%
H: 0.0%
C: -7.15%
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: -0.69%
H: 2.32%
C: -0.12%
therapy growth study market
Adverum Biotechnologies to Present LUNA Preliminary Efficacy and Safety Data at the 47th Annual Meeting of the Macula Society
Published: 2023-12-07 (Crawled : 21:00) - globenewswire.com
ADVM | $11.515 1.45% 25K
|
Health Technology
|
| O: 0.99%
H: 1.96%
C: -11.75%
biotechnologies meeting
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001415889-24-007715 | 4 | 2024-03-12 | 2023-10-03 | Buy | A | 85000 | 85000 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 78% | 22% |
Top 10 Gainers
AGBA | $1.05 162.5% 100M
|
Finance
INVO | $1.36 78.95% 3.6M
|
Health Technology
BPTH | $5.62 73.46% 75M
|
Health Technology
TIRX | $0.8231 69.78% 54M
|
ISPC | $0.307 44.13% 3.6M
|
Professional, Scientific, and T...
SINT | $0.0519 39.14% 350M
|
Health Technology
XPON | $2.63 36.27% 8.4M
|
ALRN | $5.53 30.12% 250K
|
Health Technology
VTNR S | $1.26 28.68% 9.1M
|
Industrial Services
HOLO | $2.86 27.68% 28M
|
Last 48 Hours Insiders Buying
TPL P 3 | $592.6 1.31% 22K
|
Miscellaneous
|
15:00
RELL | $10.24 3.85% 36K
|
Electronic Technology
|
13:30
IZEA | $2.53 16K
|
Technology Services
|
00:00
RKT P 383 | $11.735 3.12% 640K
|
Finance
|
22:30
CTRN P 18090 | $23.035 2.97% 16K
|
Retail Trade
|
22:00
BRN P 10650 | $2.8 0.36% 44K
|
Energy Minerals
|
21:00
NEOG P 10000 | $12.07 -0.58% 840K
|
Health Technology
|
16:30
RMCF | $3.53 1.7K
|
Consumer Non-Durables
|
20:10